Jubilant Pharmova Ltd

Jubilant Pharmo Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Jubilant Pharmova Ltd

₹ 740 -1.27%
28 Jun - close price
jubl.com BSE: 530019 NSE: JUBLPHARMA
About

Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs.[1]

Key Points

Business Segments & Revenue Contribution 9MFY24[1][2]
a) Radiopharma (~44%): Radiopharmaceuticals (including radiopharmacies)The company is the #3 radiopharmaceutical manufacturer in the US and has the #2 network in the US with 46 radiopharmacies. In 9MFY24, sale of Mertiatide, Sulfur colloid) and Ruby-Fill did very well. RUBY-FILL is a cardiac imaging product. Company plans to maintain its leadership position in North America.[3]

Website BSE NSE
  • Market Cap ₹ 11,784 Cr.
  • Current Price ₹ 740
  • High / Low ₹ 775 / 319
  • Stock P/E 373
  • Book Value ₹ 149
  • Dividend Yield 0.68 %
  • ROCE 2.60 %
  • ROE 1.32 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has been maintaining a healthy dividend payout of 171%

Cons

  • Stock is trading at 4.96 times its book value
  • The company has delivered a poor sales growth of -25.6% over past five years.
  • Company has a low return on equity of 2.89% over last 3 years.
  • Earnings include an other income of Rs.103 Cr.
  • Working capital days have increased from 82.8 days to 136 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
366 179 151 155 241 205 223 183 200 217 186 175 206
311 172 154 173 220 209 216 185 198 213 186 176 194
Operating Profit 55 7 -3 -18 20 -4 7 -2 2 4 1 -1 12
OPM % 15% 4% -2% -11% 8% -2% 3% -1% 1% 2% 0% -0% 6%
14 4 106 9 7 10 106 8 14 16 18 19 50
Interest 12 3 3 3 3 3 4 6 6 6 7 8 8
Depreciation 11 9 9 9 9 9 11 12 11 11 12 12 13
Profit before tax 46 -1 92 -21 15 -6 98 -11 -1 2 0 -2 42
Tax % 23% 23% 6% 27% 32% 20% 7% 47% -2,467% 17% 300% -4% 22%
35 -1 86 -16 10 -5 92 -6 -31 2 -0 -2 32
EPS in Rs 2.21 -0.05 5.42 -0.98 0.66 -0.33 5.76 -0.37 -1.93 0.12 -0.03 -0.15 2.04
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
3,142 3,666 3,172 2,656 2,491 3,306 3,439 3,140 2,710 88 810 785
2,650 3,076 2,890 2,344 2,173 2,765 3,112 2,765 2,282 95 807 768
Operating Profit 492 590 282 312 318 541 326 375 427 -7 3 16
OPM % 16% 16% 9% 12% 13% 16% 9% 12% 16% -8% 0% 2%
-90 -198 305 62 52 45 72 168 48 126 138 103
Interest 263 285 233 201 174 135 129 136 102 31 19 30
Depreciation 152 175 107 87 81 83 86 107 100 6 43 48
Profit before tax -13 -68 246 86 115 368 183 299 273 82 79 42
Tax % -238% 101% 17% 16% 31% 28% 20% -7% 21% 5% 37% 24%
-43 1 205 73 79 263 148 321 214 78 50 32
EPS in Rs -2.72 0.05 12.88 4.58 4.97 16.54 9.27 20.16 13.46 4.93 3.13 1.98
Dividend Payout % -110% 5,652% 23% 65% 60% 18% 49% 25% 37% 101% 160% 252%
Compounded Sales Growth
10 Years: -14%
5 Years: -26%
3 Years: -34%
TTM: -3%
Compounded Profit Growth
10 Years: -18%
5 Years: -27%
3 Years: -47%
TTM: -36%
Stock Price CAGR
10 Years: 15%
5 Years: 11%
3 Years: 1%
1 Year: 86%
Return on Equity
10 Years: 6%
5 Years: 7%
3 Years: 3%
Last Year: 1%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 16 15 16 16 16 16 16 16 16 16 16 16
Reserves 1,828 1,717 1,929 1,998 2,027 2,233 2,324 2,591 1,267 1,266 2,399 2,359
3,263 3,314 2,279 1,808 1,698 1,424 1,702 2,013 504 507 346 378
1,385 1,604 963 507 651 951 821 814 58 41 248 240
Total Liabilities 6,492 6,651 5,188 4,329 4,391 4,625 4,864 5,433 1,845 1,829 3,008 2,992
2,185 2,151 1,446 1,415 1,421 1,438 1,491 1,865 127 124 687 711
CWIP 213 242 20 36 65 115 284 59 0 0 47 37
Investments 1,979 2,006 1,766 1,709 1,710 1,706 1,764 1,764 1,646 1,646 1,657 1,657
2,114 2,251 1,955 1,169 1,195 1,365 1,325 1,746 71 60 618 587
Total Assets 6,492 6,651 5,188 4,329 4,391 4,625 4,864 5,433 1,845 1,829 3,008 2,992

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
827 549 286 164 419 558 182 317 608 -4 -65 143
-399 -194 1,319 522 -43 -127 -285 -198 178 93 31 -40
-446 -361 -1,647 -784 -338 -470 85 -41 -782 -107 23 -78
Net Cash Flow -18 -6 -42 -98 38 -40 -18 78 5 -18 -12 25

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 46 53 37 47 57 54 51 49 0 88 85 90
Inventory Days 132 135 97 119 127 120 87 142 0 276 258
Days Payable 111 110 96 91 136 154 106 134 145 155
Cash Conversion Cycle 67 77 38 75 47 21 32 58 0 88 216 193
Working Capital Days 53 -51 63 44 48 27 44 83 -2 -42 155 136
ROCE % 8% 9% 6% 7% 7% 14% 8% 10% 12% 6% 4%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
50.68% 50.68% 50.68% 50.68% 50.68% 50.67% 50.67% 50.67% 50.67% 50.67% 50.67% 50.67%
24.82% 23.14% 23.18% 23.45% 23.47% 23.06% 23.38% 23.22% 23.20% 23.20% 20.29% 19.06%
1.75% 1.03% 1.06% 0.63% 0.62% 1.60% 1.62% 1.62% 1.63% 1.64% 2.89% 3.77%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.24% 0.00% 0.00% 0.00% 0.00%
22.68% 25.09% 25.01% 25.18% 25.17% 24.59% 24.20% 23.11% 23.91% 23.89% 25.56% 25.91%
0.07% 0.07% 0.07% 0.07% 0.07% 0.07% 0.13% 0.13% 0.59% 0.59% 0.58% 0.58%
No. of Shareholders 87,4931,13,7761,09,4201,08,0631,09,4101,05,6321,00,21297,93593,37589,37686,58892,264

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls